Share |
News

Verisante Technology, Inc. Announces Exclusive Distribution Agreement with Clarion Medical Technologies Inc.


March 15, 2012 at 2:00 pm

COMPANY TO ATTEND AMERICAN ACADEMY OF DERMATOLOGY’S
70TH ANNUAL MEETING IN SAN DIEGO, CALIFORNIA

VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt: V3T) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that the Company has entered into an exclusive agreement with Clarion Medical Technologies Inc. (“Clarion”) to distribute Verisante Aura™ in Canada.  

“Clarion has broad and deep relationships with the leading dermatologists and dermatology clinics across Canada and a wealth of experience in introducing innovative technologies to the dermatological industry,” said Thomas Braun, President & CEO of Verisante.  “With a reputation for distributing superior products and providing exceptional service, we believe Clarion is the ideal partner to  assist us in the sales, distribution, and servicing of Verisante Aura™ within Canada.”

Clarion has a current line of products that directly relate to UV damage and skin care treatments, in addition to dermatological products and devices utilizing optical technologies for a variety of other medical applications, making Verisante Aura™ a natural addition to this existing product line.

“Clinical study results have shown that Verisante Aura™ is a device that has the potential to revolutionize the way skin cancer is diagnosed,” said Dan Webb, CEO of Clarion.  “Clarion is very excited to be the Aura’s exclusive distributor in Canada and to be able to bring this life-saving technology to medical professionals across the country.”

Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura™ is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.

Verisante also announced it will have an information and education booth at the American Academy of Dermatology conference in San Diego, CA from March 17-19 (booth #2825).

About Clarion Medical Technologies

Formerly known as Coherent-AMT, Clarion Medical Technologies Inc. is a medical distributor of innovative technology solutions, operating in Canada since 1989. Over that time, Clarion has gained a superior reputation for dedication to the Canadian healthcare community, serving Canadian hospitals and private practices with best-in-class products, comprehensive education and business building programs, award winning technical support and many more unique services.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale. 

Verisante Aura™ was recently awarded Popular Science Magazine’s “Best of What’s New Award” for 2011, and Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.  In addition, the Company was named a finalist for the 2011 Regional Awards for New Technology by the Canadian Manufacturers & Exporters and the National Research Council of Canada and named as the year’s top ranking Technology and Life Sciences Company on the TSX Venture 50.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. 

Company Contact:

Thomas Braun, President & CEO
Verisante Technology, Inc.
Telephone: (604) 605-0507
Email: info@verisante.com

Website:  www.verisante.com  
Youtube:  www.youtube.com/verisante  
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante

Forward Looking Statements 

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

 

 

  Back to top